Stock market today: Dow, S&P 500, Nasdaq slide as government shutdown looms, inflation data improves but still sticky
Published On Dec 20, 2024, 9:31 AM
US stocks experienced a rough day as the House of Representatives voted against a Trump-supported spending bill, increasing the risk of a government shutdown. Key inflation data showed a slowdown in price increases for November, impacting investor sentiment. The Nasdaq Composite fell 0.8%, while the S&P 500 and Dow Jones dropped by 0.5% and 0.4%, respectively. Major tech stocks, including Nvidia and AMD, saw declines. Novo Nordisk’s stock plunged over 20% after disappointing drug trial results.
Stock Forecasts
NVO
Negative
The potential for a government shutdown could lead to increased volatility in the stock markets, particularly affecting sectors reliant on government spending. Inflation data indicating decelerating price gains could influence Federal Reserve policy and interest rates, thereby affecting tech stocks. Additionally, Novo Nordisk's failure in drug trials represents a significant blow to investors and may lower confidence in pharmaceutical investments.
XLK
Negative
The negative sentiment around tech stocks due to external pressures like government uncertainty may lead to further declines, particularly in high-growth stocks and sectors. The performance of large caps in these sectors could stabilize if broader market reassurances come from the Fed's stance on interest rates.
Related News
Stock market today: Dow, S&P 500, Nasdaq futures sell-off as government shutdown looms, inflation data improves but still sticky
Dec 20, 2024, 8:53 AM
Stocks signaled another rough day of trading on Friday after the House of Representatives voted against a Trump-backed spending bill.
FDA finalizes decision to end Lilly's GLP-1 shortage, analysts predict Novo will be next
Dec 19, 2024, 3:57 PM
The FDA decided the shortage for Eli Lilly's GLP-1 tirzepatide has finally come to an end.
Elon Musk, RFK Jr., Dr. Oz, and the coming clash over Ozempic
Dec 18, 2024, 10:49 AM
Biden officials recently proposed allowing Medicare to start covering GLP-1 medications to treat obesity. It's unclear whether Trump's administration will see it through.